廣告
香港股市 已收市

  • 恒指

    18,963.68
    +425.87 (+2.30%)
     

  • 國指

    6,718.86
    +158.19 (+2.41%)
     

  • 上證綜指

    3,154.55
    +0.23 (+0.01%)
     

  • 滬深300

    3,666.28
    +1.72 (+0.05%)
     

  • 美元

    7.8130
    -0.0008 (-0.01%)
     

  • 人民幣

    0.9243
    +0.0009 (+0.10%)
     

  • 道指

    39,512.84
    +125.08 (+0.32%)
     

  • 標普 500

    5,222.68
    +8.60 (+0.16%)
     

  • 納指

    16,340.87
    -5.40 (-0.03%)
     

  • 日圓

    0.0499
    -0.0001 (-0.18%)
     

  • 歐元

    8.4154
    -0.0083 (-0.10%)
     

  • 英鎊

    9.7820
    -0.0020 (-0.02%)
     

  • 紐約期油

    78.20
    -1.06 (-1.34%)
     

  • 金價

    2,366.90
    +26.60 (+1.14%)
     

  • Bitcoin

    60,891.87
    -1,702.80 (-2.72%)
     

  • CMC Crypto 200

    1,258.17
    -99.84 (-7.35%)
     

Centene Agrees To Divest Magellan Specialty Health To Evolent Health

Vandana Singh
·1 分鐘文章

  • Evolent Health Inc (NYSE: EVH) has agreed to acquire NIA (also known as Magellan Specialty Health), the specialty benefit management organization owned by Centene Corporation (NYSE: CNC).

  • The organization focuses on managing cost and quality in radiology, musculoskeletal, physical medicine, and genetics.

  • Deal consideration includes $650 million at the close plus additional contingent consideration of up to $150 million based on 2023 performance.

  • The upfront consideration will be partly funded by $250 million in Evolent shares issued at $29.50, a 24% premium to the prior day's closing price.

  • Upon close, the NIA team and platform will be fully integrated into Evolent's value-based specialty care business, which includes New Century Health, Vital Decisions, and IPG.

  • NIA has revenues of approximately $250 million and a standalone adjusted EBITDA of approximately $50 million.

  • The transaction is anticipated to be immediately accretive to adjusted EBITDA margins and cash flow.

  • Highly complementary business is expected to add $85 million of high-visibility Adjusted EBITDA by 2024.

  • Diversifies Evolent's revenue base and increases cross-sell opportunity from $16 billion to $50 billion.

  • In addition to the NIA acquisition, Evolent and Centene are expanding Centene's relationship with NIA and extending NIA's contracts with Centene through 2027. These expansions will generate at least $20 million of Adjusted EBITDA by the fourth quarter of 2024.

  • Price Action: EVH shares closed at $23.86 on Thursday.

See more from Benzinga

廣告

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.